Vireo Growth (VREOF) Common Equity (2020 - 2026)
Vireo Growth (VREOF) reported Common Equity of $294.1 million for Q1 2026, up 482.38% on a YoY basis from $50.5 million in Q1 2025, and down 4.33% sequentially from $307.4 million in Q4 2025.
Vireo Growth (VREOF) Common Equity (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Common Equity data on file, last reported at $294.1 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 482.38% year-over-year to $294.1 million; the trailing twelve-month figure through Mar 2026 stood at $294.1 million (up 482.38% YoY), and the FY2025 full-year result was $307.4 million, up 452.88% from the prior year.
- Common Equity declined to $294.1 million in Q1 2026, from $307.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $307.4 million in Q4 2025 to a low of -$22.6 million in Q1 2024.
- A 5-year average of $70.6 million and a median of $16.5 million in 2022 frame the typical range for Common Equity.
- Across the five-year window, Common Equity tumbled 991.83% in 2024 and surged 2338.48% in 2025, its largest moves.
- Tracing VREOF's Common Equity over 5 years: stood at $3.4 million in 2022, then sank by 566.27% to -$16.0 million in 2023, then surged by 446.55% to $55.6 million in 2024, then soared by 452.88% to $307.4 million in 2025, then retreated by 4.33% to $294.1 million in 2026.
- Business Quant data shows VREOF's Common Equity at $294.1 million in Q1 2026, $307.4 million in Q4 2025, and $246.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 294.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 294.10 Mn |
| Dec 31, 2025 | 307.40 Mn |
| Sep 30, 2025 | 246.31 Mn |
| Jun 30, 2025 | 268.58 Mn |
| Mar 31, 2025 | 50.50 Mn |
| Dec 31, 2024 | 55.60 Mn |
| Sep 30, 2024 | -11.00 Mn |
| Jun 30, 2024 | -22.56 Mn |
| Mar 31, 2024 | -22.58 Mn |
| Dec 31, 2023 | -16.04 Mn |
| Sep 30, 2023 | -12.85 Mn |
| Jun 30, 2023 | -7.92 Mn |
| Mar 31, 2023 | -2.07 Mn |
| Dec 31, 2022 | 3.44 Mn |
| Sep 30, 2022 | 16.48 Mn |
| Jun 30, 2022 | 24.00 Mn |
| Mar 31, 2022 | 29.08 Mn |
| Dec 31, 2021 | 43.01 Mn |
| Sep 30, 2021 | 53.81 Mn |
| Jun 30, 2021 | 59.77 Mn |